Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US Would Cough Up As Much As $31bn More For Rx-Only DXM Over 10 Years

Nov 08 2016

• By Eileen Francis

Related Content

Developing Antitussive Alternatives To DXM Would Offset Commercial Risk

Sep 27 2010

FDA Panel Says Leave DXM Unscheduled For Now, Urges Congressional Action

Sep 20 2010

DXM Sales Age Restriction Reaches Florida; CHPA Navigates PSE Road

Apr 08 2016

CBO Overestimates Costs Of Enforcing DXM Sales Age-Restriction – CHPA

Jul 08 2016

Industry Roundup: DXM Bill Moves, CHPA Biz Dev VP, Neurobrands Injunction

Apr 25 2016

Education To Prevent Abuse Reinforces DMX Safety As OTC – CHPA Study

Jul 01 2016

Related Companies

Procter & Gamble

GSK plc

Additional Topics

United States Drug Approval Standards FDA OTC Drugs Respiratory Consumer

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window